This article is more than 5 years old. Information may no longer be current.
Study: Ocriplasmin achieves better VMT release rates than in MIVI-TRUST, but concerns remain
Click Here to Manage Email Alerts
SAN FRANCISCO — Greater rates of vitreomacular traction release were achieved with ocriplasmin compared with rates reported in the MIVI-TRUST studies, according to a study presented here, yet concerns remain regarding treatment-related adverse events, particularly loss of visual acuity.
“Ocriplasmin for VMT release was effective in 45% of eyes, higher than what was seen in the MIVI-TRUST studies and also higher than what is seen in natural history,” Jennifer I. Lim, MD, said at the American Society of Retina Specialists annual meeting, where she reported results of a Macula Society retrospective collaborative review. “However, of concern is that we did see that complications were not uncommon.”
Jennifer I. Lim, MD
The study consisted of an online electronic survey sent to the Macula Society membership to gather data on eyes with vitreomacular traction, with or without macular hole, treated with intravitreal Jetrea (ocriplasmin, ThromboGenics) and no other treatments within 3 months and followed up for at least 4 weeks. A total of 208 patients were included in the results.
At baseline, 41 eyes (20%) had lamellar hole, and 75 eyes (36%) had full-thickness macular hole, with 12 of those macular holes measuring 400 µm or greater. Retinal flap was present in 31 eyes (41%).
After treatment with ocriplasmin alone, vitreomacular adhesion was released in 44% of eyes at 1 week, and at the final visit, 12 weeks or longer, the rate was 45% in eyes without pars plana vitrectomy and 74% in eyes with pars plana vitrectomy.
Higher rates of vitreomacular traction release were achieved in eyes with macular holes than in those without: 64% vs. 40% at week 4 (P = .001), with no statistically significant difference seen in closure rates among various hole sizes.
Regarding complications, Lim said, “As expected, visual color and contrast disturbances occurred in about 15%, retinal tear or retinal detachment occurred in about 3%, and of most concern, visual acuity loss of three or more lines at the final visit occurred in about 6%.” – by Patricia Nale, ELS
Reference:
Lim J. Macula Society collaborative retrospective study of ocriplasmin for vitreomacular traction. Presented at: American Society of Retina Specialists annual meeting; Aug. 9-14, 2016; San Francisco.
Disclosure: Lim reports she is a consultant for Alcon.